Eterna Therapeutics Inc (ERNA) ニュース

Form PRE 14A - Other preliminary proxy statements

Form 8-K - Current report

Form 8-K - Current report

Form 8-K - Current report

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs i

The presentation reports the development of a beta 2 microglobulin-knockout (B2M-KO) iMSC line with enhanced...

Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory Board

CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the...

Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on the Development of a mRNA-Engineered iPSC Line which Mimics Native B2M Expression, via Targeted Insertion of HLA-E at the B2M Locus

Eterna reports the development of an mRNA-engineered iPSC line developed using UltraSlice™ to express a...

Eterna Therapeutics Announces the Appointment of Peter Cicala, JD, to its Board of Directors

CAMBRIDGE, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the...

Form 3 - Initial statement of beneficial ownership of securities

Form 8-K - Current report

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]